Company Announcement
25 August 2017

PACIFIC EDGE 2017 ANNUAL MEETING RESULTS

Pacific Edge held its Annual Meeting in Dunedin on 24 August 2017, updating shareholders on its strategic progress, particularly in the US which is the company's primary opportunity. A positive and supportive group of shareholders attended both in Dunedin and on-line utilising an interactive meeting platform.

Chairman Chris Gallaher affirmed Pacific Edge's key objective to be the leading molecular diagnostics technology for the detection and management of bladder cancer, and said the company was making strong progress towards its goal.

"Bringing new medical products to market, which seek to disrupt decades of standard clinical pathways takes time, investment and you must have the correct building blocks in place. We have built a strong foundation in the US with all of the necessary pieces in place to succeed in this market.

"Our company is in a long game, the opportunity before us is very significant and we are still in early stages of our life cycle. We are now on the cusp of realising this potential for the benefit of our shareholders."

CEO of Pacific Edge, David Darling, updated shareholders on progress in the year to date, citing the recently announced acceptance of Cxbladder in the Standard of Care by MidCentral District Health Board, as an example of the growing recognition of the positive benefits of Cxbladder for both patients and the healthcare provider.

"We have maintained a consistent growth strategy and are delivering on our planned outcomes. Moving forward, you can expect to see more of the same as we continue to focus on gaining traction in the US and our other targeted markets.

"We are making strong commercial progress and expect to see sales continue to grow in FY18 as the large scale organisations we are targeting transition into commercial customers and build significant sales volume. A 62% increase in operating revenue and a reduction in operating expenses of 4% over the last year is a great step forward for a young growth company.

"To now have four proprietary molecular tests providing increased clinical resolution across the entire bladder cancer pathway is a world first and sets the company up for its growth. It's now our job to monetise this," said David Darling.

Shareholders voted in favour of all resolutions at the 2017 Annual Meeting.

Resolution	For	Against	Abstain
Re-election of David Darling	159,924,076 87.34%	23,180,250 12.66%	309,654
Re-election of Bryan Williams	160,037,010 87.36%	23,157,600 12.64%	219,370
Authorise Directors to fix the auditors' remuneration	183,067,177 99.95%	90,109 0.05%	256,694

Copies of the annual meeting presentation and speeches are available on the company website www.pacificedgedx.com

ENDS

Company Announcement
25 August 2017

For more information contact:
David Darling, Chief Executive Officer, Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies.

Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and better detection and management of urothelial cancer. Cxbladder Triage, Detect and Monitor are available through the company's dedicated CLIA-certified laboratories for customers in New Zealand, Australia, Singapore and the USA. Cxbladder Resolve launched in New Zealand in December 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients' urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the company's CLIA certified laboratories. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient specific clinical factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured from a small quantity of a patient's urine, with patient characteristics for the identification of patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.